Parmax Pharma share news, announcements and annual reports
BSE: 540359Pharmaceuticals & BiotechnologySmall Cap
Parmax Pharma Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Mar 2017
Last close ₹135.05down ₹1.35 (0.99%)
Share price at the BSE close on 26 Oct 2026. Previous close ₹136.40.
26 Oct: open ₹135.05, high ₹135.05, low ₹135.05
52-week range of traded prices to 26 Oct 2026
₹22.60Low, 25 Mar 2026₹139.10High, 5 Oct 2026
- Under BSE's graded surveillance, stage 0, on the list for 28 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹93 Cr4,411th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- Shares changed
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business.
- Net worth zero or below
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −70.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- Net worth zero or below
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 657
Parmax Pharma board meetings
107 filed, newest first. Page 2 of 3.
Aug 2022
May 2022
23 May · Board meeting
Meeting on 30 May 2022: audited results
Feb 2022
7 Feb · Board meeting
Meeting on 14 Feb 2022: quarterly results
Nov 2021
13 Nov · Board meeting
3 Nov · Board meeting
Meeting on 13 Nov 2021: quarterly results
Aug 2021
14 Aug · Board meeting
14 Aug · Board meeting
9 Aug · Board meeting
Meeting on 14 Aug 2021: quarterly results
Jun 2021
23 Jun · Board meeting
Meeting on 29 Jun 2021: quarterly results and audited results
Feb 2021
4 Feb · Board meeting
Meeting on 12 Feb 2021: quarterly results
Jan 2021
16 Jan · Board meeting
11 Jan · Board meeting
Meeting on 16 Jan 2021: preferential issue of shares
Nov 2020
5 Nov · Board meeting
Meeting on 12 Nov 2020: quarterly results
Sep 2020
10 Sep · Board meeting
Meeting on 15 Sep 2020: annual general meeting and quarterly results
Jul 2020
28 Jul · Board meeting
Meeting on 31 Jul 2020: audited results
Feb 2020
5 Feb · Board meeting
Meeting on 12 Feb 2020: quarterly results
Nov 2019
6 Nov · Board meeting
Meeting on 14 Nov 2019: quarterly results
Aug 2019
2 Aug · Board meeting
Meeting on 9 Aug 2019: quarterly results
May 2019
23 May · Board meeting
Meeting on 30 May 2019: audited results
Apr 2019
26 Apr · Board meeting
Meeting on 26 Apr 201926 Apr · Board meeting
Mar 2019
11 Mar · Board meeting
Meeting on 17 Mar 2019
Feb 2019